Ascletis Announces U.S. FDA Clearance Of Ind Application For Its Oral Small Molecule Il-17 Inhibitor, ASC50, For The Treatment Of Psoriasis
May 22 (Reuters) - Ascletis Pharma Inc 1672.HK:
ASCLETIS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ITS ORAL SMALL MOLECULE IL-17 INHIBITOR, ASC50, FOR THE TREATMENT OF PSORIASIS
ASCLETIS PHARMA INC - PHASE I TRIAL DOSING EXPECTED TO START IN Q3 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.